3644 results for «2683»
3644 results
Disrupting the aorta and valves: the next transcatheter wave
18 May 2026 – From EuroPCR 2026
Delve into the next wave of transcatheter interventions disrupting the aorta and valves. This session covers pioneering minimally invasive ascending aortic repair, novel polymeric aortic valve implants, and innovative devices for tricuspid repair and leaflet replacement.
Is durability still a topic of concern for TAVI patients? What are the remaining challenges that we need to overcome?
20 May 2026 – From EuroPCR 2026
Examine the clinical relevance of TAVI valve durability and its impact on long-term patient management in aortic stenosis. Review key factors influencing valve performance over time, with a focus on procedural and anatomical determinants of optimal outcomes.
Current concepts and techniques aimed at achieving ideal valve expansion...
The Physiology Course - Introduction
18 May 2026 – From EuroPCR 2026
The Physiology Course introduction welcomes participants and provides an overview of the importance of coronary physiology, outlining the program designed in collaboration with EuroPCR.
The physiological mindset: foundations every modern operator must own
18 May 2026 – From EuroPCR 2026
This session delves into the fundamental principles governing coronary blood flow regulation, emphasizing coronary autoregulation and the influence of epicardial haemodynamics on vascular morphology. Participants deepen their understanding of coronary physiology beyond formulas, exploring the intersection of physiology and atherosclerosis.
TAVI vs. surgery - Are the latest long-term data creating a dilemma for aortic stenosis patients?
21 May 2026 – From EuroPCR 2026
This session critically evaluates the latest long-term data comparing transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR). It explores differing perspectives between surgeons and interventional cardiologists regarding valve durability and lifetime management, fostering a high-quality debate to achieve consensus within Heart Team discussions...
CathWorks FFRangio: from clinical data to advanced patient care
21 May 2026 – From EuroPCR 2026
Explore the clinical value of the CathWorks FFRangio system through the lens of the ALL-RISE randomised controlled trial and its implications for daily practice. By reviewing the trial’s primary and secondary endpoints, examine how FFRangio may influence diagnostic assessment, treatment planning, and clinical decision-making in patients...
Physiology in the real world: how to measure, when to trust it, what to do?
18 May 2026 – From EuroPCR 2026
This session provides comprehensive insights into coronary physiology assessment tools, emphasizing techniques for reliable haemodynamic measurements and exploring clinical considerations surrounding coronary spasms and myocardial bridges.
Rapid fire session on next generation structural heart and valve therapies
18 May 2026 – From EuroPCR 2026
An intensive rapid-fire session presenting the latest advancements in next-generation structural heart and valve therapies, including novel transcatheter systems for aortic and mitral valve repair, innovative solutions for tricuspid regurgitation, and implant-free PFO closure technologies.
Renal denervation in China: momentum, insights, and evolution
21 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session highlights the rapidly evolving clinical experience of renal denervation (RDN) in China following regulatory approval, with a focus on real-world practice and programme development.
It reviews how structured, patient-centred hypertension pathways are being integrated with RDN, alongside practical strategies for managing complex renal...
The metal-free strategy: shaping the new era of hybrid vessel restoration with DCB and BRS
19 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session explores the emerging metal-free strategy in coronary intervention, combining drug-coated balloons (DCB) and bioresorbable scaffolds (BRS) to support a “leave-nothing-behind” approach to vessel restoration.
It focuses on lesion preparation, scaffold sizing and deployment, and the integration of hybrid therapies to optimise procedural outcomes....
Rapid fire session on vascular innovation, interventional technologies and hypertension
18 May 2026 – From EuroPCR 2026
This rapid fire session showcased cutting-edge innovations in vascular interventions, interventional technologies, and hypertension management. Highlights included three-dimensional OCT-guided ultrafast laser atherectomy for calcified lesions, a novel biodegradable metallic stent, intelligent pressure-controlled perfusion to prevent acute limb ischemia, a microneedle balloon catheter, personalized arterial hypertension control...
Rethinking stentless PCI strategy - Improving outcomes with Bioadaptor
19 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session explores contemporary PCI strategies through the concept of stentless intervention using the Bioadaptor device in complex coronary disease.
It highlights the bioadaptive design features of Bioadaptor and reviews the supporting clinical evidence, with a focus on how this technology may influence procedural outcomes.
The...
The microcirculation: the next frontier in coronary practice
18 May 2026 – From EuroPCR 2026
Delve into the complexities of coronary microcirculation and its clinical implications. This session highlighted advanced diagnostic techniques such as bolus and continuous thermodilution, the interpretation of microvascular resistance reserve, and practical guidance on establishing a high-impact ANOCA clinic to manage microvascular angina and coronary dysfunction.
How to become a CHAMPION in LAA closure
19 May 2026 – From EuroPCR 2026
This session reviews the latest CHAMPION AF trial data and its implications for left atrial appendage (LAA) closure in patients with atrial fibrillation.
It explores how emerging evidence may influence clinical practice and patient selection, and how LAA closure could evolve across different atrial fibrillation populations.
A recorded...
The Jon DeHaan Foundation Award competition
18 May 2026 – From EuroPCR 2026
Explore the forefront of interventional cardiology innovation with the Jon DeHaan Foundation Award competition, featuring pioneering solutions for valvular heart disease and mechanical support. This session highlights novel devices such as TriFlo for tricuspid regurgitation, the extravascular ventricular assist device (eVAD System), and the first-in-human experience...
Management of a patient with complex multivessel disease involving bifurcations
19 May 2026 – From EuroPCR 2026
Complex multivessel coronary disease involving bifurcations requires careful procedural planning, imaging guidance and tailored stent strategies.
This EuroPCR 2026 session combines live educational case with insights from the NAGOMI COMPLEX study to explore contemporary approaches to complex PCI. A key focus is placed on the role of...
Innovating heart failure care: from real-time monitoring to mechanical support
18 May 2026 – From EuroPCR 2026
Innovations in heart failure care are transforming patient management, from real-time, non-invasive congestion monitoring to advanced mechanical support systems. This session presents the Anusar congestion assessment tool, early clinical data on the NuPulse intravascular ventricular assist system for ambulatory support, and explores AI-driven voice biomarker technology...
Landmark interventional randomised controlled trial data and practice guidelines to transform pulmonary embolism care
19 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session presents landmark randomised controlled trial data shaping interventional treatment of pulmonary embolism, with a focus on translating evidence into clinical practice.
It reviews the HI-PEITHO trial and its implications in intermediate-risk acute PE, where ultrasound-assisted catheter-directed thrombolysis (USCDT) reduced the composite endpoint of...
Once you find microvascular disease, what do you actually do?
18 May 2026 – From EuroPCR 2026
Addressing coronary microvascular disease requires a comprehensive understanding of current medical therapies and emerging interventions. This session reviews state-of-the-art pharmacological treatments, elucidates the mechanisms and clinical data surrounding the coronary sinus reducer (CSR), and offers critical discussion on its therapeutic role in microvascular dysfunction.
Early evidence from a next generation coronary sinus reducer for the treatment of coronary microvascular dysfunction
20 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session presents early clinical experience with a next-generation self-expanding nitinol coronary sinus reducer for patients with coronary microvascular dysfunction. It reviews practical aspects of device implantation and discusses initial findings from the SERRA I feasibility study, providing insight into this emerging therapeutic approach....
